Want to see FDMT full AI Analyst Report?
Top Page
4D Molecular Therapeutics
(NASDAQ:FDMT)
Select Model
Select Model
Rating:60Neutral
Price Target:
$12.00
▲(14.39% Upside)
Action:Reiterated
Date:06/29/26
FDMT scores a 60 primarily due to weak current fundamentals (large losses and significant ongoing cash burn) partially offset by a low-debt balance sheet and improved revenue scale. Technicals are a key support, with the stock trading above all major moving averages and a positive MACD. Corporate financing news is supportive for liquidity, but adds secured-debt/covenant complexity, while valuation remains difficult to justify on earnings due to negative profitability.
Positive Factors
Proprietary engineered AAV vector platform
4D's engineered AAV platform provides a durable technological moat: tissue-targeted delivery increases potential efficacy and tolerability across indications, raises partner interest, and supports differentiated clinical candidates that can drive long-term licensing, royalty and product opportunities.
Negative Factors
Sustained negative operating cash flow
Large, persistent cash burn creates ongoing funding needs and increases likelihood of dilutive financings or reliance on milestone/loan draws. Over a multi-quarter horizon this cash flow profile can constrain R&D pacing, force prioritization of programs, and elevate execution risk absent recurring product revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary engineered AAV vector platform
4D's engineered AAV platform provides a durable technological moat: tissue-targeted delivery increases potential efficacy and tolerability across indications, raises partner interest, and supports differentiated clinical candidates that can drive long-term licensing, royalty and product opportunities.
Read all positive factors
4D Molecular Therapeutics (FDMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$679.59M
Dividend YieldN/A
Average Volume (3M)736.92K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth383560.87%
EPS Growth20.87%
CountryUS
Employees227
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.66
Shares Outstanding52,276,253
10 Day Avg. Volume751,996
30 Day Avg. Volume736,921
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue4.99
Enterprise Value/Gross Profit-40.11
Enterprise Value/Ebitda-2.70
Forecast
1Y Price Target
$30.33Price Target Upside189.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.03
Revenue Forecast (FY)$12.23M
4D Molecular Therapeutics Business Overview & Revenue Model
Company Description
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a ...
How the Company Makes Money
FDMT generates revenue primarily through collaboration and licensing arrangements rather than product sales (its programs are clinical-stage and it has not consistently generated recurring commercial product revenue). Under these agreements, FDMT ...
4D Molecular Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
68
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 88.24M | 85.21M | 37.00K | 20.72M | 3.13M | 18.04M |
| Gross Profit | -10.98M | 77.58M | -141.26M | -76.37M | -77.12M | -43.32M |
| EBITDA | -163.43M | -132.48M | -154.16M | -96.63M | -105.09M | -69.79M |
| Net Income | -160.90M | -140.11M | -160.87M | -100.84M | -107.49M | -71.32M |
Balance Sheet | ||||||
| Total Assets | 512.90M | 566.71M | 560.38M | 339.89M | 261.85M | 353.49M |
| Cash, Cash Equivalents and Short-Term Investments | 390.89M | 402.65M | 424.88M | 288.23M | 213.55M | 247.78M |
| Total Debt | 20.54M | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M |
| Total Liabilities | 61.07M | 61.05M | 49.78M | 32.06M | 30.51M | 34.38M |
| Stockholders Equity | 451.84M | 505.66M | 510.61M | 307.83M | 231.34M | 319.11M |
Cash Flow | ||||||
| Free Cash Flow | -130.06M | -109.08M | -138.37M | -78.56M | -98.22M | -78.24M |
| Operating Cash Flow | -129.45M | -109.08M | -134.59M | -75.79M | -86.69M | -69.13M |
| Investing Cash Flow | -56.03M | -92.97M | -302.44M | 115.72M | -17.05M | -172.68M |
| Financing Cash Flow | 124.44M | 112.96M | 337.25M | 156.83M | 3.08M | 118.09M |
4D Molecular Therapeutics Technical Analysis
Positive
10.49
Price Trends
9.81
Positive
9.57
Positive
9.47
Positive
Market Momentum
0.96
Negative
69.82
Neutral
78.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Positive. The current price of 10.49 is above the 20-day moving average (MA) of 10.43, above the 50-day MA of 9.81, and above the 200-day MA of 9.47, indicating a bullish trend. The MACD of 0.96 indicates Negative momentum. The RSI at 69.82 is Neutral, neither overbought nor oversold. The STOCH value of 78.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FDMT.
4D Molecular Therapeutics Risk Analysis
4D Molecular Therapeutics disclosed 87 risk factors in its most recent earnings report. 4D Molecular Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
4D Molecular Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $679.59M | -4.89 | -36.83% | ― | 383560.87% | 20.87% | |
57 Neutral | $976.83M | -13.03 | -33.07% | ― | ― | -20.34% | |
53 Neutral | $201.92M | -1.20 | -117.86% | ― | -20.31% | -23.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $549.73M | -47.83 | -4.21% | ― | 121.11% | 80.74% | |
45 Neutral | $335.78M | -4.44 | -0.11% | ― | ― | 40.79% | |
43 Neutral | $800.60M | -4.37 | -78.12% | ― | ― | 7.21% |
* Healthcare Sector Average
FDMT
4D Molecular Therapeutics
13.00
9.05
229.11%
ASMB
Assembly Biosciences
27.74
9.60
52.92%
KRRO
Korro Bio
14.00
1.42
11.29%
DSGN
Design Therapeutics
15.64
12.10
341.81%
IMRX
Immuneering
5.19
1.14
28.15%
AURA
Aura Biosciences Inc
7.74
1.58
25.65%
4D Molecular Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
4D Molecular Therapeutics Secures $200 Million Loan Facility
Positive
Jun 29, 2026
On June 24, 2026, 4D Molecular Therapeutics entered into a senior secured Loan and Security Agreement with Hercules Capital that provides for up to $200 million in term loans maturing on June 1, 2031, with an initial $20 million drawn at closing a...
Executive/Board ChangesShareholder Meetings
4D Molecular Therapeutics Stockholders Back Directors and Governance
Positive
Jun 22, 2026
On June 17, 2026, 4D Molecular Therapeutics held its 2026 Annual Meeting of Stockholders virtually, with 44,038,022 of 52,274,735 eligible shares represented, and stockholders elected three Class III directors—Nancy Miller-Rich, John F. Mill...
Business Operations and StrategyExecutive/Board Changes
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role
Positive
Mar 31, 2026
On March 25, 2026, 4D Molecular Therapeutics appointed Chief Financial Officer Kristian Humer as its Principal Accounting Officer, consolidating key financial leadership roles under a single executive. He replaces Ashoo Gupta in this capacity, who...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.